This study looked at patients with existing neuropsychiatric conditions who started taking semaglutide or other diabetes drugs like metformin. Researchers used a large US database to follow over 63,000 people for up to four years after treatment began.
The study found that, compared to other diabetes medications, semaglutide was associated with a broadly lower risk of developing various neuropsychiatric outcomes. This included significantly lower rates of substance-related disorders, mood disorders, anxiety, and several other conditions. However, the risk for dementia or CNS degenerative diseases was similar between high and low-dose semaglutide groups.
The study did not report on safety events, tolerability, or discontinuations. The main reason to be careful is that this is an observational study, so it shows links but cannot prove that semaglutide causes these effects. The findings are not practice-changing and should motivate future clinical trials.
From this, readers should understand that the research suggests a possible association, but more evidence is needed to confirm any impact on neuropsychiatric health.